

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Olaparib for adjuvant treatment of BRCA mutation-  
positive HER2-negative high-risk early breast cancer after  
chemotherapy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final appraisal determination**

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
Not applicable – no potential equality issues were identified during the scoping process.
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
Clinical experts advised that black women and younger women are more likely to develop triple negative breast cancer, a more aggressive form of early-stage breast cancer. The committee noted this but felt that their recommendations would not affect these populations differently.
3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No – not applicable.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No – not applicable.

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 31 October 2022